These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2929 related articles for article (PubMed ID: 20870100)

  • 1. Rheumatoid arthritis.
    Scott DL; Wolfe F; Huizinga TW
    Lancet; 2010 Sep; 376(9746):1094-108. PubMed ID: 20870100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current immunotherapy in rheumatoid arthritis.
    Meier FM; Frerix M; Hermann W; Müller-Ladner U
    Immunotherapy; 2013 Sep; 5(9):955-74. PubMed ID: 23998731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
    Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
    Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
    Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
    Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging trends in diagnosis and treatment of rheumatoid arthritis.
    Birch JT; Bhattacharya S
    Prim Care; 2010 Dec; 37(4):779-92, vii. PubMed ID: 21050958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
    Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
    van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
    Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
    Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
    Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheumatoid arthritis.
    Klareskog L; Catrina AI; Paget S
    Lancet; 2009 Feb; 373(9664):659-72. PubMed ID: 19157532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early rheumatoid arthritis.
    Mitchell KL; Pisetsky DS
    Curr Opin Rheumatol; 2007 May; 19(3):278-83. PubMed ID: 17414956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [PRECLINICAL RHEUMATOID ARTHRITIS].
    Elalouf O; Elkayam O
    Harefuah; 2017 Jul; 156(7):451-454. PubMed ID: 28786276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
    Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
    Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
    Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rheumatoid arthritis (updated Current Care guideline)].
    Hakala M; Hannonen P; Helve T; Korpela M; Mattila K; Möttönen T; Varis T;
    Duodecim; 2009; 125(19):2131-2. PubMed ID: 19938416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium.
    Bramlage CP; Kaps C; Ungethüm U; Bramlage P; Koziolek M; Wessels J; Krenn V; Pruss A; Müller GA; Strutz F; Burmester GR; Häupl T
    Scand J Rheumatol; 2008; 37(6):401-9. PubMed ID: 18830904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and management of early rheumatoid arthritis.
    Brown AN
    J S C Med Assoc; 2003 Oct; 99(10):296-302. PubMed ID: 14621660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 147.